Additional Strategic Funding for CartiHeal's Ongoing AGILI-C™ IDE Clinical Study

Published: 1/02/2018
Additional Strategic Funding for CartiHeal's Ongoing AGILI-C™ IDE Clinical Study
Source: WWW.BUSINESSWIRE.COM

KFAR SABA, Israel & DURHAM, N.C.--(BUSINESS WIRE)--CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5M investment from Bioventus, a global leader in orthobiologics – reflecting the growing interest in CartiHeal’s technology. Bioventus’s $2.5M boost complements CartiHeal’s latest financing rou

Read more
Related news
Comment
FACEBOOK